Advertisement
Advertisement

GANX

GANX logo

Gain Therapeutics, Inc. Common Stock

1.74
USD
Sponsored
-0.03
-1.69%
Jun 24, 16:00 UTC -4
Closed
exchange

After-Market

1.75

+0.01
+0.57%

GANX Earnings Reports

Positive Surprise Ratio

GANX beat 12 of 21 last estimates.

57%

Next Report

Date of Next Report
Aug 10, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/
-$0.14
Implied change from Q1 26 (Revenue/ EPS)
--
/
+7.69%
Implied change from Q2 25 (Revenue/ EPS)
--
/
-26.32%

Gain Therapeutics, Inc. Common Stock earnings per share and revenue

On May 11, 2026, GANX reported earnings of -0.13 USD per share (EPS) for Q1 26, beating the estimate of -0.14 USD, resulting in a 7.34% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -1.10% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 6 analysts forecast an EPS of -0.14 USD, with revenue projected to reach -- USD, implying an increase of 7.69% EPS, and increase of 0.00% in Revenue from the last quarter.
FAQ
For Q1 2026, Gain Therapeutics, Inc. Common Stock reported EPS of -$0.13, beating estimates by 7.34%, and revenue of $0.00, 0% as expectations.
The stock price moved down -1.1%, changed from $1.82 before the earnings release to $1.80 the day after.
The next earning report is scheduled for Aug 10, 2026.
Based on 6 analysts, Gain Therapeutics, Inc. Common Stock is expected to report EPS of -$0.14 and revenue of -- for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement